Correction: Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277541/
https://www.ncbi.nlm.nih.gov/pubmed/37321671
http://dx.doi.org/10.1136/rmdopen-2021-002012corr1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277541/
https://www.ncbi.nlm.nih.gov/pubmed/37321671
http://dx.doi.org/10.1136/rmdopen-2021-002012corr1

Ejemplares similares